Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,374 | 238 | 98.5% |
| Education | $67.26 | 3 | 1.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,075 | 75 | $0 (2024) |
| Gilead Sciences, Inc. | $582.33 | 33 | $0 (2024) |
| PFIZER INC. | $473.86 | 26 | $0 (2024) |
| Janssen Biotech, Inc. | $345.36 | 23 | $0 (2022) |
| GlaxoSmithKline, LLC. | $278.68 | 13 | $0 (2024) |
| Merck Sharp & Dohme LLC | $246.95 | 14 | $0 (2024) |
| Celgene Corporation | $193.38 | 16 | $0 (2023) |
| Madrigal Pharmaceuticals | $173.29 | 2 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $157.67 | 7 | $0 (2023) |
| Boston Scientific Corporation | $147.19 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $843.18 | 35 | ABBVIE INC. ($235.03) |
| 2023 | $703.65 | 35 | AbbVie Inc. ($153.46) |
| 2022 | $762.81 | 38 | Celgene Corporation ($152.62) |
| 2021 | $114.35 | 6 | Gilead Sciences, Inc. ($45.30) |
| 2020 | $134.55 | 8 | AbbVie Inc. ($35.65) |
| 2019 | $375.69 | 22 | AbbVie, Inc. ($124.60) |
| 2018 | $746.26 | 49 | AbbVie, Inc. ($260.91) |
| 2017 | $760.64 | 48 | AbbVie, Inc. ($241.13) |
All Payment Transactions
241 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.78 | General |
| 12/17/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $21.07 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $18.14 | General |
| Category: RESPIRATORY | ||||||
| 12/04/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $11.07 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $8.93 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $27.35 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/24/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $23.82 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/17/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $22.32 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/16/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $16.09 | General |
| Category: IMMUNOLOGY | ||||||
| 10/10/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/01/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $20.22 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/25/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Education | In-kind items and services | $39.56 | General |
| Category: LIVER DISEASE | ||||||
| 09/12/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $133.73 | General |
| Category: LIVER DISEASE | ||||||
| 09/12/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: ONCOLOGY | ||||||
| 09/09/2024 | ABBVIE INC. | LINZESS (Drug), VIBERZI, CREON | Food and Beverage | In-kind items and services | $15.18 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/02/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $21.52 | General |
| Category: RESPIRATORY | ||||||
| 08/30/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/29/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $24.48 | General |
| Category: RESPIRATORY | ||||||
| 06/17/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/17/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Education | In-kind items and services | $20.00 | General |
| Category: Rare Disease | ||||||
| 06/05/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $23.11 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 05/06/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $29.46 | General |
| Category: RESPIRATORY | ||||||
| 04/22/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $22.72 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 406 | 516 | $337,813 | $59,478 |
| 2022 | 10 | 357 | 468 | $261,326 | $50,419 |
| 2021 | 10 | 319 | 438 | $205,980 | $39,190 |
| 2020 | 11 | 280 | 349 | $171,533 | $41,867 |
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 91110 | Imaging of digestive tract done from the inside of the digestive tract | Office | 2023 | 14 | 15 | $26,340 | $10,228 | 38.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 41 | 41 | $74,333 | $8,383 | 11.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 52 | 52 | $14,508 | $6,026 | 41.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 25 | 57 | $9,747 | $5,682 | 58.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 48 | 68 | $12,376 | $5,330 | 43.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 50 | 50 | $80,750 | $5,116 | 6.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 57 | 57 | $67,773 | $4,282 | 6.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 27 | 29 | $9,657 | $4,214 | 43.6% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 54 | 109 | $13,516 | $3,427 | 25.4% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 13 | 13 | $5,850 | $2,495 | 42.7% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 12 | 12 | $5,400 | $2,301 | 42.6% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 13 | 13 | $17,563 | $1,994 | 11.4% |
| 91110 | Imaging of digestive tract done from the inside of the digestive tract | Office | 2022 | 13 | 13 | $22,828 | $9,432 | 41.3% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 35 | 35 | $63,455 | $6,859 | 10.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 35 | 66 | $11,286 | $5,701 | 50.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 32 | 32 | $10,656 | $5,342 | 50.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 40 | 40 | $11,160 | $4,691 | 42.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 47 | 58 | $10,556 | $4,604 | 43.6% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2022 | 63 | 131 | $16,244 | $4,180 | 25.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 43 | 44 | $52,316 | $3,624 | 6.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 35 | 35 | $56,525 | $3,232 | 5.7% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 14 | 14 | $6,300 | $2,754 | 43.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 52 | 87 | $15,834 | $6,841 | 43.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 35 | 35 | $11,655 | $5,996 | 51.4% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 25 | 25 | $45,325 | $5,345 | 11.8% |
About Dr. Timothy Tran, MD
Dr. Timothy Tran, MD is a Gastroenterology healthcare provider based in Torrance, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/20/2007. The National Provider Identifier (NPI) number assigned to this provider is 1316164171.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Timothy Tran, MD has received a total of $4,441 in payments from pharmaceutical and medical device companies, with $843.18 received in 2024. These payments were reported across 241 transactions from 28 companies. The most common payment nature is "Food and Beverage" ($4,374).
As a Medicare-enrolled provider, Tran has provided services to 1,362 Medicare beneficiaries, totaling 1,771 services with total Medicare billing of $190,953. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Location Torrance, CA
- Active Since 04/20/2007
- Last Updated 09/26/2024
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1316164171
Products in Payments
- STELARA (Biological) $392.26
- Creon (Drug) $299.33
- Humira (Biological) $294.35
- TRELEGY ELLIPTA (Drug) $255.20
- XELJANZ (Drug) $227.99
- ZEPOSIA (Drug) $193.38
- SKYRIZI (Biological) $180.80
- REZDIFFRA (Drug) $173.29
- INFLECTRA (Biological) $168.54
- DIFICID (Drug) $167.29
- ENTYVIO (Biological) $157.67
- RINVOQ (Biological) $149.63
- GENERAL BILIARY DEVICES (Device) $134.03
- XIFAXAN (Drug) $120.93
- Vemlidy (Drug) $105.58
- ZEPATIER (Drug) $79.66
- SUCRAID (Drug) $72.86
- OCALIVA (Drug) $69.72
- VOQUEZNA (Drug) $62.74
- REMICADE (Biological) $59.41
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Torrance
Dr. Tonny Lee, M.d, M.D
Gastroenterology — Payments: $133,902
Sara Kranke
Gastroenterology — Payments: $75,421
Dr. Jennifer Kolb, Md, MD
Gastroenterology — Payments: $60,794
Dr. Jerome Cohen, M.d, M.D
Gastroenterology — Payments: $38,553
Dr. Edward Piken, M.d, M.D
Gastroenterology — Payments: $23,781
Viktor Eysselein, M.d, M.D
Gastroenterology — Payments: $13,509